>Sirtris

>Sirtris, a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas.
Founded in 2004, Sirtris was one of the first pharmaceutical companies focused on the sirtuin platform and today remains the leader of innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases.

One thought on “>Sirtris

Leave a Reply

Your email address will not be published. Required fields are marked *